ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

MXCT MaxCyte Inc

3.77
-0.06 (-1.57%)
2024年5月4日 - 終了
15分遅延
名称 銘柄コード 市場 種別
MaxCyte Inc MXCT NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.06 -1.57% 3.77 07:30:10
始値 安値 高値 終値 前日終値
3.95 3.74 3.95 3.77 3.83
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/1021:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
2024/4/0221:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
2024/3/1305:05GLOBEMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
2024/3/0606:15EDGAR2Form 8-K - Current report
2024/3/0507:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/3/0506:05GLOBEMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
2024/2/2706:22EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1506:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1502:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2024/2/0922:05GLOBEMaxCyte to Report Fourth Quarter and Full Year 2023..
2024/2/0206:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/1/3106:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/3022:05GLOBEMaxCyte and Wugen Sign Strategic Platform License to..
2024/1/2706:45EDGAR2Form 8-K - Current report
2024/1/2701:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/1/2322:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
2024/1/0906:15EDGAR2Form 8-K - Current report
2024/1/0906:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
2024/1/0506:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0322:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
2024/1/0216:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
2023/12/2906:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1206:30EDGAR2Form 8-K - Current report
2023/12/1206:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
2023/12/0706:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0207:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/3006:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/3006:32EDGAR2Form 144 - Report of proposed sale of securities
2023/11/1806:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2023/11/1706:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/1622:05GLOBEMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a..
2023/11/0907:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0906:12EDGAR2Form 8-K - Current report
2023/11/0906:05GLOBEMaxCyte Reports Third Quarter 2023 Financial Results and..
2023/11/0706:05GLOBEMaxCyte to Participate in Two Upcoming Investor Conferences
2023/10/0505:14EDGAR2Form 8-K - Current report
2023/10/0505:05GLOBEMaxCyte Announces Preliminary Third Quarter 2023 Revenue and..
2023/9/0621:05GLOBEMaxCyte Appoints Ali Soleymannezhad as Executive Vice..
2023/9/0521:05GLOBEMaxCyte to Participate in Baird Global Healthcare Conference
2023/8/3106:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/8/1005:55EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/1005:16EDGAR2Form 8-K - Current report
2023/8/1005:05GLOBEMaxCyte Reports Second Quarter and Half-Year 2023 Financial..
2023/8/0121:05GLOBEMaxCyte Signs Strategic Platform License with Prime Medicine..
2023/7/2905:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/1321:05GLOBEMaxCyte to Report Second Quarter 2023 Financial Results on..
2023/7/1307:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/1105:51EDGAR2Form 144 - Report of proposed sale of securities
2023/7/1021:05GLOBEMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform..
2023/7/0621:05GLOBEMaxCyte Signs Strategic Platform License with Lyell..

最近閲覧した銘柄

Delayed Upgrade Clock